Drugs / Intravenous Immunoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06742190 Comparator | Dec 2024 → Sep 2026 overdue | multifocal motor neuropathy | argenx | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous Immunoglobulin | “IVIG (Intravenous Immunoglobulin)” NCT06742190 ↗ |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06742190 ↗ |
| Route | Intravenous | “Intravenous infusion of IVIg” NCT06742190 ↗ |